UMB Bank n.a. Purchases 138 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

UMB Bank n.a. raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 36.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 521 shares of the biotechnology company’s stock after acquiring an additional 138 shares during the quarter. UMB Bank n.a.’s holdings in Sarepta Therapeutics were worth $63,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in SRPT. Sunbelt Securities Inc. lifted its holdings in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank raised its position in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Sarepta Therapeutics in the third quarter worth $59,000. Blue Trust Inc. boosted its position in shares of Sarepta Therapeutics by 896.5% during the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 511 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Sarepta Therapeutics by 27.7% in the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 185 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on SRPT shares. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, January 14th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Price Performance

SRPT opened at $116.46 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The business has a fifty day moving average of $122.17 and a 200 day moving average of $128.47. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25. The stock has a market cap of $11.12 billion, a P/E ratio of 93.17 and a beta of 0.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.